title: Infants with ductal-dependent congenital heart defects
text: References
  |
  1. Huang FK, Lin CC, Huang TC, Weng KP, Liu PY, Chen YY, Wang HP, Ger LP, Hsieh KS. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatrics and neonatology. 2013;54:102-6.
  2. Strobel AM, Lu le N. The Critically Ill Infant with Congenital Heart Disease. Emergency medicine clinics of North America. 2015;33:501-18.
  3. Browning Carmo KA, Barr P, West M, Hopper NW, White JP, Badawi N. Transporting newborn infants with suspected duct dependent congenital heart disease on low-dose prostaglandin E1 without routine mechanical ventilation. Archives of disease in childhood Fetal and neonatal edition. 2007;92:F117-9.
  4. Lim DS, Kulik TJ, Kim DW, Charpie JR, Crowley DC, Maher KO. Aminophylline for the prevention of apnea during prostaglandin E1 infusion. Pediatrics. 2003;112:e27-9.
  5. Yucel IK, Cevik A, Bulut MO, Dedeoglu R, Demir IH, Erdem A, Celebi A. Efficacy of very low-dose prostaglandin E1 in duct-dependent congenital heart disease. Cardiology in the young. 2015;25:56-62.
  6. Lucron H, Chipaux M, Bosser G, Le Tacon S, Lethor JP, Feillet F, Burger G, Monin P, Marcon F. [Complications of prostaglandin E1 treatment of congenital heart disease in paediatric medical intensive care]. Archives des maladies du coeur et des vaisseaux. 2005;98:524-30.
  7. Meckler GD, Lowe C. To intubate or not to intubate? Transporting infants on prostaglandin E1. Pediatrics. 2009;123:e25-30.
  8. Finan E, Mak W, Bismilla Z, McNamara PJ. Early discontinuation of intravenous prostaglandin E1 after balloon atrial septostomy is associated with an increased risk of rebound hypoxemia. Journal of perinatology : official journal of the California Perinatal Association. 2008;28:341-6.
  9. Arai K. [The intrapulmonary metabolism of prostaglandin E1 in patients with pulmonary hypertension]. Masui The Japanese journal of anesthesiology. 1995;44:536-41.
  10. Watt K, Li JS, Benjamin DK, Jr., Cohen-Wolkowiez M. Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. Journal of cardiovascular pharmacology. 2011;58:126-32.
  11. Kaufman MB, El-Chaar GM. Bone and tissue changes following prostaglandin therapy in neonates. The Annals of pharmacotherapy. 1996;30:269-74, 77.
  12. Perme T, Mali S, Vidmar I, Gvardijancic D, Blumauer R, Mishaly D, Grabnar I, Nemec G, Grosek S. Prolonged prostaglandin E1 therapy in a neonate with pulmonary atresia and ventricular septal defect and the development of antral foveolar hyperplasia and hypertrophic pyloric stenosis. Upsala journal of medical sciences. 2013;118:138-42.
  13. Soyer T, Yalcin S, Bozkaya D, Yigit S, Tanyel FC. Transient hypertrophic pyloric stenosis due to prostoglandin infusion. Journal of perinatology : official journal of the California Perinatal Association. 2014;34:800-1.
  15. Australian Injectable Drugs Handbook, 6th Edition, Society of Hospital Pharmacists of Australia 2014
  16. Micromedex solutions. Truven health analytics. Accessed via CIAP 14/12/15
  |